Progression of MGUS-SMM-MM
Session V of Myeloma2018 saw experts Jose Martinez-Climent, MD, Celine Vachon, PhD, Niels Weinhold, PhD, and Elisabet Manasanch, MD, speak on the pathobiological and clinical aspects of the development of multiple myeloma, from monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM). The stimulating presentations in this session focus on mouse modelling, the prognostic molecular techniques, and genetic mechanisms associated with predisposition to MM.
Presentations
University of Navarra, Pamplona, Spain
Jose Martinez-Climent, MD, from the University of Navarra, Pamplona, Spain, explores modelling MM development in mice models.
Mayo Clinic, Rochester, MN
Celine Vachon, PhD, from the Mayo Clinic, Rochester, MN, speaks on genetic predispositions to myeloma.
UAMS Myeloma Institute, Little Rock, AR
Niels Weinhold, PhD, from the UAMS Myeloma Institute, Little Rock, AR, talks about single cell sequencing in MGUS and SMM.
MD Anderson Cancer Center, Houston, TX
Elisabet Manasanch, MD, from the MD Anderson Cancer Center, Houston, TX, discusses clinical insights in MM progression.
